Literature DB >> 31576312

Stereotactic body radiation therapy could improve disease control in oligometastatic patients with renal cell carcinoma: do we need more evidence?

Linda Agolli1,2.   

Abstract

Entities:  

Year:  2019        PMID： 31576312      PMCID： PMC6685909          DOI： 10.21037/atm.2019.05.05

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  22 in total

1.  Systematic lymph node dissection in lung metastasectomy of renal cell carcinoma: an 18 years of experience.

Authors:  S Renaud; P E Falcoz; M Alifano; A Olland; P Magdeleinat; O Pagès; J F Regnard; G Massard
Journal:  J Surg Oncol       Date:  2014-03-12       Impact factor: 3.454

2.  Role of Stereotactic Body Radiation Therapy for the Management of Oligometastatic Renal Cell Carcinoma.

Authors:  Ciro Franzese; Davide Franceschini; Lucia Di Brina; Giuseppe Roberto D'Agostino; Pierina Navarria; Tiziana Comito; Pietro Mancosu; Stefano Tomatis; Marta Scorsetti
Journal:  J Urol       Date:  2019-01       Impact factor: 7.450

3.  Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma.

Authors:  Peter J Wersäll; Henric Blomgren; Ingmar Lax; Karl-Mikael Kälkner; Christina Linder; Göran Lundell; Bo Nilsson; Sten Nilsson; Ingemar Näslund; Pavel Pisa; Christer Svedman
Journal:  Radiother Oncol       Date:  2005-06-20       Impact factor: 6.280

4.  Resection of metastatic renal cell carcinoma.

Authors:  J P Kavolius; D P Mastorakos; C Pavlovich; P Russo; M E Burt; M S Brady
Journal:  J Clin Oncol       Date:  1998-06       Impact factor: 44.544

5.  Renal cell cancer histological subtype distribution differs by race and sex.

Authors:  Loren Lipworth; Alicia K Morgans; Todd L Edwards; Daniel A Barocas; Sam S Chang; S Duke Herrell; David F Penson; Matthew J Resnick; Joseph A Smith; Peter E Clark
Journal:  BJU Int       Date:  2015-06-02       Impact factor: 5.588

6.  Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma.

Authors:  Danai D Daliani; Nizar M Tannir; Christos N Papandreou; Xuemei Wang; Stephen Swisher; Christopher G Wood; David A Swanson; Christopher J Logothetis; Eric Jonasch
Journal:  BJU Int       Date:  2009-03-31       Impact factor: 5.588

7.  Surgery for metastases of renal cell carcinoma: outcome of treatments and preliminary assessment of Leuven-Udine prognostic groups in the targeted therapy era.

Authors:  Sara V Tornberg; Harri Visapää; Tuomas P Kilpeläinen; Kimmo Taari; Riikka Järvinen; Kaisa Erkkilä; Harry Nisen; Petrus Järvinen
Journal:  Scand J Urol       Date:  2019-01-20       Impact factor: 1.612

8.  Stereotactic body radiotherapy (SBRT) for pulmonary metastases from renal cell carcinoma-a multicenter analysis of the German working group "Stereotactic Radiotherapy".

Authors:  Juliane Hoerner-Rieber; Marciana Duma; Oliver Blanck; Guido Hildebrandt; Andrea Wittig; Fabian Lohaus; Michael Flentje; Frederick Mantel; Robert Krempien; Michael J Eble; Klaus Henning Kahl; Judit Boda-Heggemann; Stefan Rieken; Matthias Guckenberger
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

9.  Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to Thoracic, Abdominal, and Soft Tissue Lesions Using Stereotactic Body Radiotherapy (SBRT).

Authors:  Basel Altoos; Arya Amini; Muthanna Yacoub; Maria T Bourlon; Elizabeth E Kessler; Thomas W Flaig; Christine M Fisher; Brian D Kavanagh; Elaine T Lam; Sana D Karam
Journal:  Radiat Oncol       Date:  2015-10-28       Impact factor: 3.481

10.  Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis.

Authors:  Daniele Santini; Raffaele Ratta; Francesco Pantano; Delia De Lisi; Marco Maruzzo; Luca Galli; Elisa Biasco; Azzurra Farnesi; Sebastiano Buti; Cora Nanette Sternberg; Linda Cerbone; Giuseppe Di Lorenzo; Silvia Spoto; Michelle Sterpi; Ugo De Giorgi; Rossana Berardi; Mariangela Torniai; Andrea Camerini; Francesco Massari; Giuseppe Procopio; Giuseppe Tonini
Journal:  Oncotarget       Date:  2017-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.